Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Allogene TherapeuticsEli Lilly
Last price
$1.25$1,273.46
Currency
USD
USD
$432M$1.1T
-42.75
-$0.65$29.79
0.470.45
0$6.69
00.54%
Sector
HealthHealth
Employees
15150,000
Ticker
$ALLO$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ALLO or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.